BMO Capital analyst Kostas Biliouris has maintained their bullish stance on SLN stock, giving a Buy rating yesterday.
Kostas Biliouris has given his Buy rating due to a combination of factors surrounding Silence Therapeutics’ strategic positioning and potential market opportunities. The decision to pause the Lp(a) program until a partnership is secured is seen as a prudent move, allowing the company to focus on its promising polycythemia vera (PV) program. This shift in focus is expected to capture investor interest, especially given the attractive market dynamics demonstrated by Jakafi’s significant sales in the PV space.
Biliouris also highlights the potential of Divesiran in the PV market, noting its strong efficacy and favorable safety profile, which differentiate it from competitors. The anticipated positive outcomes from ongoing trials and potential partnerships for Zerlasiran further bolster the stock’s upside potential. Additionally, the undervaluation of SLN, coupled with the promising prospects of its pipeline programs, supports the Buy rating, as these factors collectively suggest significant growth opportunities for the company.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $30.00 price target.
SLN’s price has also changed dramatically for the past six months – from $19.000 to $4.720, which is a -75.16% drop .